Published in Vaccine Weekly, July 26th, 2006
Prezista, a new HIV protease inhibitor, is approved to be co-administered with a low-dose of ritonavir and other active anti-HIV agents. Ritonavir, a protease inhibitor approved in 1996, slows the breakdown of Prezista in the body thereby increasing the concentration of Prezista in the patient's system.
Infection with HIV causes AIDS, which results in more than 15,000 premature deaths each year in the United States and more than 2.8...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly